Central nervous system relapse in acute promyelocytic leukaemia treated with ATRA.
نویسندگان
چکیده
All-trans retinoic acid (ATRA) is currently recommended as standard treatment for acute promyelocytic leukaemia (APL). However, there has been increasing concern that ATRA is associated with unusual sites of relapse. We present three cases of APL previously treated with ATRA who ultimately relapsed within the central nervous system (CNS) and hypothesize that, by up-regulating intercellular adhesion molecules, ATRA may facilitate the passage of malignant promyelocytes across the blood-brain barrier.
منابع مشابه
Central nervous system relapse occurs in about 5% of cases of acute promyelocytic leukaemia.
In this report, we present images from a patient with acute promyelocytic leukemia who experienced several central nervous system relapses.
متن کاملCentral nervous system haemorrhage causing early death in acute promyelocytic leukaemia.
Acute promyelocytic leukaemia (APL) is a rare type of paediatric leukaemia characterised by a specific genetic mutation and life-threatening coagulopathy. The discovery of all-trans retinoic acid (ATRA), which acts directly on promyelocytic locus-retinoic acid receptor α (PML-RARα) gene product, brought a revolution to the therapy of this disorder. Unfortunately, despite an improvement in the c...
متن کاملTamibarotene in patients with acute promyelocytic leukaemia relapsing after treatment with all-trans retinoic acid and arsenic trioxide.
Treatment of acute promyelocytic leukaemia (APL) with arsenic trioxide (ATO) and all-trans retinoic acid (ATRA) is highly effective first-line therapy, although approximately 5-10% of patients relapse. Tamibarotene is a synthetic retinoid with activity in APL patients who relapse after chemotherapy and ATRA, but has not been studied in relapse after treatment with ATO and ATRA. We report on a p...
متن کاملTreatment outcomes in relapsed acute promyelocytic leukemia patients initially treated with all-trans retinoic acid and arsenic compound-based combined therapies
Contemporary combined therapies that include the use of all-trans retinoic acid (ATRA) and arsenic compounds have reduced relapse rates from ~50 to <10% in acute promyelocytic leukemia (APL) patients, however relapse treatment remains controversial. Treatment outcomes in relapsed patients with APL previously treated with combined ATRA + arsenic compound therapy were investigated. A retrospectiv...
متن کاملAcute promyelocytic leukaemia presenting with subarachnoid haemorrhage and complicated by central nervous system involvement
Acute promyelocytic leukaemia (APML) is a condition classically characterised by t(15;17) (q22, q21), with disseminated intravascular coagulopathy (DIC) being a major cause of death. Central nervous system (CNS) involvement with APML commonly occurs in relapse; however, it is rarely seen at presentation, with only six reported cases in the literature. This case is the first to describe a patien...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
عنوان ژورنال:
- American journal of hematology
دوره 71 1 شماره
صفحات -
تاریخ انتشار 1997